These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 7931245

  • 1. Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: preclinical and clinical findings.
    Henriot S, Kuhn C, Kettler R, Da Prada M.
    J Neural Transm Suppl; 1994; 41():321-5. PubMed ID: 7931245
    [Abstract] [Full Text] [Related]

  • 2. MAO-B inhibition in rabbit tissues and in human platelets by Ro 19-6327 shows similar time-course.
    Kettler R, Cesura AM, Dingemanse J, Da Prada M.
    J Neural Transm Suppl; 1990; 32():211-4. PubMed ID: 2089093
    [Abstract] [Full Text] [Related]

  • 3. In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl.
    Bondiolotti GP, Galva MD, Villa F, Sciaba L, Picotti GB.
    Biochem Pharmacol; 1995 Jun 29; 50(1):97-102. PubMed ID: 7605351
    [Abstract] [Full Text] [Related]

  • 4. Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327.
    Bench CJ, Price GW, Lammertsma AA, Cremer JC, Luthra SK, Turton D, Dolan RJ, Kettler R, Dingemanse J, Da Prada M.
    Eur J Clin Pharmacol; 1991 Jun 29; 40(2):169-73. PubMed ID: 1906004
    [Abstract] [Full Text] [Related]

  • 5. Antioxidant activity of the monoamine oxidase B inhibitor lazabemide.
    Mason RP, Olmstead EG, Jacob RF.
    Biochem Pharmacol; 2000 Sep 01; 60(5):709-16. PubMed ID: 10927030
    [Abstract] [Full Text] [Related]

  • 6. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.
    Youdim MB, Gross A, Finberg JP.
    Br J Pharmacol; 2001 Jan 01; 132(2):500-6. PubMed ID: 11159700
    [Abstract] [Full Text] [Related]

  • 7. [3H]Ro 19-6327: a reversible ligand and affinity labelling probe for monoamine oxidase-B.
    Cesura AM, Galva MD, Imhof R, Kyburz E, Picotti GB, Da Prada M.
    Eur J Pharmacol; 1989 Mar 29; 162(3):457-65. PubMed ID: 2744079
    [Abstract] [Full Text] [Related]

  • 8. Combined treatment with MAO-A inhibitor and MAO-B inhibitor increases extracellular noradrenaline levels more than MAO-A inhibitor alone through increases in beta-phenylethylamine.
    Kitaichi Y, Inoue T, Nakagawa S, Boku S, Izumi T, Koyama T.
    Eur J Pharmacol; 2010 Jul 10; 637(1-3):77-82. PubMed ID: 20406628
    [Abstract] [Full Text] [Related]

  • 9. Pharmacodynamics of lazabemide, a reversible and selective inhibitor of monoamine oxidase B.
    Holford NH, Guentert TW, Dingemanse J, Kettler R.
    Br J Clin Pharmacol; 1994 Jun 10; 37(6):553-7. PubMed ID: 7917773
    [Abstract] [Full Text] [Related]

  • 10. Design and early clinical evaluation of selective inhibitors of monoamine oxidase.
    Palfreyman MG, McDonald IA, Bey P, Schechter PJ, Sjoerdsma A.
    Prog Neuropsychopharmacol Biol Psychiatry; 1988 Jun 10; 12(6):967-87. PubMed ID: 3266532
    [Abstract] [Full Text] [Related]

  • 11. Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain.
    Saura J, Kettler R, Da Prada M, Richards JG.
    J Neurosci; 1992 May 10; 12(5):1977-99. PubMed ID: 1578281
    [Abstract] [Full Text] [Related]

  • 12. Monoamine oxidase inhibition by moclobemide and 2-amino-ethyl carboxamide derivatives: mode of action and kinetic characteristics.
    Cesura AM, Muggli-Maniglio D, Lang G, Imhof R, Da Prada M.
    J Neural Transm Suppl; 1990 May 10; 32():165-70. PubMed ID: 2089085
    [Abstract] [Full Text] [Related]

  • 13. Ro 19-6327, a reversible and highly selective monoamine, oxidase B inhibitor: a novel tool to explore the MAO-B function in humans.
    Haefely WE, Kettler R, Keller HH, Da Prada M.
    Adv Neurol; 1990 May 10; 53():505-12. PubMed ID: 2122653
    [No Abstract] [Full Text] [Related]

  • 14. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
    Da Prada M, Kettler R, Keller HH, Burkard WP, Muggli-Maniglio D, Haefely WE.
    J Pharmacol Exp Ther; 1989 Jan 10; 248(1):400-14. PubMed ID: 2783611
    [Abstract] [Full Text] [Related]

  • 15. Design, synthesis and biological evaluation of lazabemide derivatives as inhibitors of monoamine oxidase.
    Zhou S, Chen G, Huang G.
    Bioorg Med Chem; 2018 Sep 15; 26(17):4863-4870. PubMed ID: 30143367
    [Abstract] [Full Text] [Related]

  • 16. [3H]Ro 16-6491, a selective probe for affinity labelling of monoamine oxidase type B in human brain and platelet membranes.
    Cesura AM, Imhof R, Takacs B, Galva MD, Picotti GB, Da Prada M.
    J Neurochem; 1988 Apr 15; 50(4):1037-43. PubMed ID: 3126263
    [Abstract] [Full Text] [Related]

  • 17. Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327.
    Fowler JS, Volkow ND, Logan J, Schlyer DJ, MacGregor RR, Wang GJ, Wolf AP, Pappas N, Alexoff D, Shea C.
    Neurology; 1993 Oct 15; 43(10):1984-92. PubMed ID: 8413955
    [Abstract] [Full Text] [Related]

  • 18. MAO-B inhibition by a single dose of l-deprenyl or lazabemide does not prevent neuronal damage following focal cerebral ischaemia in rats.
    Jolkkonen J, Kauppinen R, Nyman L, Haapalinna A, Sivenius J.
    Pharmacol Toxicol; 2000 Nov 15; 87(5):242-5. PubMed ID: 11129505
    [Abstract] [Full Text] [Related]

  • 19. MDL 72,974A: a selective MAO-B inhibitor with potential for treatment of Parkinson's disease.
    Palfreyman MG, McDonald IA, Zreika M, Cremer G, Haegele KD, Bey P.
    J Neural Transm Suppl; 1993 Nov 15; 40():101-11. PubMed ID: 8294896
    [Abstract] [Full Text] [Related]

  • 20. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
    Aubin N, Barneoud P, Carter C, Caille D, Sontag N, Marc C, Lolivier J, Gardes A, Perron C, Le Kim A, Charieras T, Pandini M, Burnier P, Puech F, Jegham S, George P, Scatton B, Curet O.
    J Pharmacol Exp Ther; 2004 Sep 15; 310(3):1171-82. PubMed ID: 15178694
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.